Novo Nordisk scientific boss sets expectations for blockbuster hopeful; Senator trumpets biotech-friendly bill;

Conversations on Twitter :

 @FierceBiotech: Nanomaterial propels animals' heart attack-damaged hearts to repair themselves. Article | Follow @FierceBiotech

 @JohnCFierce: Sen. Gillibrand wants to create a $200M marketing fund for biotechs. From petri dish to marketplace? Report | Follow @JohnCFierce

 @RyanMFierce: Orbimed has backed Intercept Pharma in a $30M C round with lead drug for primary biliary cirrhosis. Release | Follow @RyanMFierce

> Novo Nordisk ($NVO) chief scientist Mads Krogsgaard tells Reuters, unsurprisingly, that without really good results from a Phase III study of the company's hemophilia candidate, vatreptacoq alfa, the blockbuster program will be dropped.  Article

> Hungry for funding after reorganizing key partnerships, Infinity Pharmaceuticals ($INFI) has priced an offering of 5.3 million shares for $14.50 per share. Item

> U.S. Sen. Kirsten Gillibrand talked up a proposed bill that would create a bank aimed at providing universities with funding to commercialize discoveries and create jobs in industries such as biotech. Report

> Drug developer Galenea expanded its alliance with the CHDI Foundation to continue research of new drugs for Huntington's disease. Release

> Computers help researchers tackle drug-resistant bugs. Abstract

Pharma News

 @FiercePharma: Special reports this week: Top 11 Fastest-Growing Generics Companies | Top 10 Drug Advertising Spends -- Q1 2012.  | Follow @FiercePharma

> New statins study sorts out diabetes risks. More

> Roche blockbuster Avastin does well as brain tumor therapy. Story

> Forest board yields in investor lawsuits. Article

> Generic cream price spikes have experts scratching their heads. Report

Medical Device News

@FierceMedDev: St. Jude's recalled Riata leads get slapped again. News | Follow @FierceMedDev

 @MarkHFierce: BG Medicine has pulled a 510(k) filing for a cardiac disease test. Shockingly, investors weren't happy. Story | Follow @MarkHFierce

 @DamianFierce: Despite losing $7M on three recalls, CareFusion posted an income boost for fiscal Q4. News  | Follow @DamianFierce

> Luminex scores $11.6M deal for biothreat Dx. Article

> Exact Sciences seeks $50.2M in public offering. More

And Finally… The U.K.'s humble answer to Warren Buffett has written a new book that explores the future of biotech and the impact of computer-aided genomics research. Item

Suggested Articles

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes.